Smart drug targets Hard-to-Treat breast cancer

NCT ID NCT04965766

Recruiting now Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests a drug called patritumab deruxtecan in people with advanced hormone-receptor-positive breast cancer that has stopped responding to hormone therapy and chemotherapy. The drug is designed to seek out and destroy cancer cells that have a protein called HER3 on their surface. About 139 participants will receive the drug every three weeks. Researchers will track how many patients' tumors shrink and study which patients benefit most.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: patritumab deruxtecan (U3-1402)
What this could lead to: If it works, this could offer a new treatment option for people with advanced breast cancer that has stopped responding to hormone therapy and chemotherapy.
What could go wrong: This is a Phase 2 trial, so it is still early. The drug may not shrink tumors in enough patients, and side effects could be serious. Results may not apply to all breast cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Locations

CHU de Limoges
RECRUITING

Limoges, 87042, France
Centre Antoine Lacassagne
RECRUITING

Nice, 06189, France
Centre Georges François Leclerc
ACTIVE_NOT_RECRUITING

Dijon, 21079, France
Centre Léon Bérard
RECRUITING

Lyon, 69373, France
Gustave Roussy
RECRUITING

Villejuif, 94805, France
Hôpital Tenon
RECRUITING

Paris, 75020, France
Institut Claudius Regaud
RECRUITING

Toulouse, 31059, France
Institut Curie
RECRUITING

Paris, 75005, France
Institut Paoli Calmettes
RECRUITING

Marseille, 13273, France
Institut Régional du Cancer de Montpellier
RECRUITING

Montpellier, 34298, France
Institut de Cancérologie de l'Ouest
RECRUITING

Saint-Herblain, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.